分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Global molecular landscape of early MASLD progression in human obesity

Qing Zhao, William De Nardo, Ruoyu Wang, Yi Zhong, Umur Keles, Gabriele Sakalauskaite, Li Na Zhao, Huiyi Tay, Sonia Youhanna, Mengchao Yan, Ye Xie, Youngrae Kim, Sungdong Lee, Rachel Liyu Lim, Guosho

Journal:eLife

IF:0

DOI:10.7554/eLife.109534

PMID:

Published:2026-03-23

research field:分子生物学代谢组学肝脏疾病研究转录组学系统生物学肝病学

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is often asymptomatic early on but can progress to irreversible conditions like cirrhosis. Due to limited access to human liver biopsies, systematic and integrative molecular resources remain scarce. In this study, we performed transcriptomic analyses on liver and metabolomic analyses on liver and plasma samples from morbidly obese individuals without liver pathology or at early-stage MASLD. While the plasma metabolomic profile did not fully mirror liver histological features, dual-omics integration of liver samples revealed significantly remodeled lipid and amino acid metabolism pathways. Integrative network analysis uncoupled metabolic remodeling and gene expression as independent features of hepatic steatosis and fibrosis progression, respectively. Notably, GTPases and their regulators emerged as a novel class of genes linked to early liver fibrosis. This study offers a detailed molecular landscape of early MASLD in obesity and highlights potential targets of obesity-linked liver fibrosis.

本文使用的Yeasen产品

购物车
客服
转染试用